Blaine McKee
Direktor/Vorstandsmitglied bei VBI VACCINES INC.
Vermögen: - $ am 30.04.2024
Aktive Positionen von Blaine McKee
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VBI VACCINES INC. | Direktor/Vorstandsmitglied | 11.01.2019 | - |
Independent Dir/Board Member | 11.01.2019 | - | |
OrbiMed Israel Partners LP
OrbiMed Israel Partners LP Investment ManagersFinance OrbiMed Israel Partners LP seeks investment opportunities in life science companies located in Israel. The fund targets companies operating in the fields of biotechnology, pharmaceutical, medical device and diagnostics. It provides financing for seed, early, later and growth stage capital requirements. | Direktor/Vorstandsmitglied | - | - |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | Vorstandsvorsitzender | 01.01.2020 | - |
Präsident | 01.01.2020 | - |
Karriereverlauf von Blaine McKee
Ehemalige bekannte Positionen von Blaine McKee
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IMMUNOGEN, INC. | Corporate Officer/Principal | 25.04.2018 | 31.12.2019 |
New York Pharma Forum, Inc.
New York Pharma Forum, Inc. Information Technology ServicesTechnology Services New York Pharma Forum, Inc. provides information technology services for the healthcare industry. The private company is based in New York, NY. | Direktor/Vorstandsmitglied | 01.01.2014 | 01.01.2019 |
HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Direktor/Vorstandsmitglied | 10.03.2016 | 04.06.2018 |
Independent Dir/Board Member | 10.03.2016 | 04.06.2018 | |
SHIRE | Corporate Officer/Principal | 01.07.2014 | 01.04.2018 |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 01.01.2015 | 01.01.2017 |
LYRA THERAPEUTICS, INC. | Corporate Officer/Principal | 01.11.2011 | 01.06.2014 |
░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░ ░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Blaine McKee
Colorado State University | Undergraduate Degree |
Massachusetts Institute of Technology | Doctorate Degree |
MIT Sloan School of Management | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 13 |
Irland | 2 |
Operativ
Director/Board Member | 6 |
Corporate Officer/Principal | 4 |
Independent Dir/Board Member | 2 |
Sektoral
Health Technology | 7 |
Consumer Services | 3 |
Finance | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
LYRA THERAPEUTICS, INC. | Health Technology |
HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Health Technology |
IMMUNOGEN, INC. | Health Technology |
VBI VACCINES INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
New York Pharma Forum, Inc.
New York Pharma Forum, Inc. Information Technology ServicesTechnology Services New York Pharma Forum, Inc. provides information technology services for the healthcare industry. The private company is based in New York, NY. | Technology Services |
OrbiMed Israel Partners LP
OrbiMed Israel Partners LP Investment ManagersFinance OrbiMed Israel Partners LP seeks investment opportunities in life science companies located in Israel. The fund targets companies operating in the fields of biotechnology, pharmaceutical, medical device and diagnostics. It provides financing for seed, early, later and growth stage capital requirements. | Finance |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | Health Services |
- Börse
- Insiders
- Blaine McKee
- Erfahrung